NYSE Euronext accueille Novagali Pharma sur son marché européen

Paris, 22 July 2010 – Novagali Pharma, a pharmaceutical company that develops ophthalmic innovative products for treatment of all segments of the eye, today celebrated its listing on NYSE Euronext Paris.

Novagali Pharma (ticker symbol: NOVA) was admitted to NYSE Euronext by the listing of 6,359,882 existing shares making up its capital, 3,409,092 new shares resulting from the conversion of convertible bonds ('OCABSA') and the exercise of equity warrants ('BSAOCA'), 36,808 new shares granted in connection with the capital increase reserved to employees, and 6,468,750 new shares issued as part of a global offering, after the full exercise of the Over-Allotment Option. The total amount raised was €22 million. The admission and issue price of Novagali Pharma shares was set at €3.40 each. The company’s market capitalization on the day of admission amounted to €55.3 million.

Press Release Footer

About Euronext
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With nearly 1,900 listed issuers and around €6.3 trillion in market capitalisation as of end September 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

_Disclaimer
_{This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.}

_{This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at}_{www.euronext.com/terms-use}_.